As most of the previously observed effects of IL-6 on the growth of prostate cancer cells were examined in vitro, this study is the first to demonstrate the following evidence that overexpression of IL-6 in LNCaP cells enhanced their sensitivity to androgen withdrawal both in vitro and in vivo, resulting in marked growth inhibition immediately after androgen ablation. The gene discussed is IL6; the disease is prostate carcinoma.